The fibrin glue market is expected to grow at a CAGR of 10.9% between 2017-2023, to reach $3.6 billion by 2023. Rising healthcare expenditure, increasing number of surgical procedures and burn cases are some of the key factors, driving the growth of the market. Additionally, increasing prevalence of chronic diseases, aging population, low chances of complications associated with these products and increase in road accidents also support the growth of the global market.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/fibrin-glue-market/report-sample

In terms of application, the global fibrin glue market is categorized into cardiac surgery, general surgery, vascular surgery, pulmonary surgery, neurosurgery, lacerations of liver and spleen, burn bleeding, orthopedic surgery, plastic surgery, wound management, and others. Some of the other applications of fibrin glue based products include gastrointestinal surgery, hernia management, forniceal reconstruction surgery, pterygium and strabismus surgery, amniotic membrane transplantation, lamellar corneal grafting, management of conjunctival wound leaks after trabeculectomy, lid surgery, adnexal surgery. Cardiac surgery held the largest share of the global fibrin glue market in 2016. Fibrin based sealants are used for hemostasis and tissue adherence during cardiac surgeries to avoid the loss of blood, which is one of the most critical issue encountered while performing a cardiac surgery.

Europe is the second largest market for fibrin glue products, accounting for 24.4% of the global fibrin glue industry in 2016. The growth in the European fibrin glue market is mainly attributable to the increasing aging population and rising number of surgical procedures performed for the treatment of the circulatory system diseases in the region. Among the countries in Europe, Germany held the largest share of the European market for fibrin glue, contributing 26.2% in 2016. However, the market in France is expected to witness the highest growth during the forecast period. France was also the second largest market for fibrin glue products in 2016 in Europe, accounting for a 14.6% share, which is expected to increase to 15.5% by 2023, growing at a CAGR of 10.7% during the forecast period. The U.K. is the third largest market in Europe and is also expected to witness double digit growth during the forecast period.

Explore Report at: https://www.psmarketresearch.com/market-analysis/fibrin-glue-market

Some of the key players operating in the global fibrin glue market include Vivostat A/S, Kaketsuken, Johnson & Johnson, Baxter International Inc., CSL Behring, Zimmer Biomet Holdings, Inc., Takeda Pharmaceutical Company Limited, Mallinckrodt Plc, Shanghai RAAS Blood Products Co. Ltd. and Hualan Biological Engineering Inc.

The single-cell analysis market size is projected to reach $5.3 billion by 2022, growing at a CAGR of 18.1% between 2016-2022. The market is driven by factors such as increasing healthcare expenditure, growing geriatric population, high prevalence of infectious diseases, technological advancements in single-cell analysis products, and growing focus on personalized medicines.

Get a Sample Copy of This Report at: https://www.psmarketresearch.com/market-analysis/single-cell-analysis-market/report-sample

The European single-cell analysis market is expected to reach $1.6 billion by 2022. The market in Europe is witnessing growth mainly due to increasing prevalence of chronic diseases and infectious diseases, increase in the aging population, increase in the number of conferences & symposiums and increasing healthcare expenditure.  In terms of the type of product, the European single-cell analysis industry for consumables is expected to witness the fastest growth between 2016-2022. Also, in terms of the type of cell, the European single-cell analysis industry for human cell is expected to generate the highest revenue in 2022.

Personalized medicine offers tailored medical treatment to individual characteristics, needs and preferences of patients. Single cell genomics help in identifying the disease and in providing solutions to the ill patients. A single-cell analysis technique, such as flow cytometry, provides single-cell capture of specified cells with correlation to each cell's individual phenotype, which would help in drug development. A number of initiatives and consortia have been organized to collect and synthesize individual single-cell data. The application of personalized medicine to tackle rare diseases is easily achievable with single-cell analysis. With the advancement in single-cell analysis techniques, patients are treated and monitored more precisely and effectively to meet their individual needs and thereby driving the growth of the worldwide single-cell analysis market.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=single-cell-analysis-market

Competitive Analysis

Some of the key companies operating in the single-cell analysis market include Thermo Fisher Scientific Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Illumina, Inc., Bio-Rad Laboratories, Inc., QIAGEN N.V., Merck KGaA, Nanostring technologies, Agilent Technologies, Fluidigm Corporation.

The global biosimulation market is growing significantly due to technological advancements and increasing research and development investment in the pharmaceutical and biotechnology industries. Low success rate of drug approval and emerging software applications of biosimulation technology are creating ample opportunities for the global biosimulation technology market to grow at a significant rate in the forecasted period.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/biosimulation-technology-market/report-sample

In biosimulation industry, there is a trend of collaboration and partnership of universities and research institutes with suppliers. Drug discovery and development process is stringent, time consuming, and expensive process. In addition, the success rate of drug approval is very low. According to Tufts Centre for the Study of Drug Development, an academic, non-profit research group at Tufts University, in the U.S., out of 1,000 compounds tested only one makes it to human clinical trials, and out of five such compounds only one gets approved. Biosimulation technology overcomes these limitations by simulating biological systems through software models and increasing predictability in early stages of drug development; hence, saving time and money in drug development process.

Geographically, North America will be leading the global biosimulation technology market in the coming years due to technological advancements, growth in biosimilars and biologics market, high healthcare expenditure, and presence of a large number of pharmaceuticals and biotechnology companies. In addition, the U.S. Food and Drug Administration (FDA), strongly recommends simulation process in drug discovery and development; hence, fueling the growth of biosimulation technology market in North America. Europe is the fastest growing region in the global biosimulation technology market. The major reasons for the fastest growth in the region are high healthcare expenditure and increasing research and development activities.

Browse Full Report at: https://www.psmarketresearch.com/market-analysis/biosimulation-technology-market

Some of the major players operating in the global biosimulation technology market Dassault Systemes SA, Simulation Plus Inc., Certara USA, Inc., Advanced Chemistry Development, Inc., In Silico Biosciences, Inc., Chemical Computing Group, Inc., Physiomics PLC., Rhenovia Pharma Ltd., Genedata AG, Entelos Holding Corporation, Leadscope, Inc., and Schrodinger Inc. among others.

The increasing R&D investments from pharmaceutical companies and extensive drug pipelines for the treatment of various chronic diseases, such as immunological disorders, metabolic disorders, and neurological disorders, are the predominant growth drivers for the global healthcare contract research organization market. Additionally, the increasing outsourcing of pharmaceutical and biopharmaceutical R&D activities, high failure rate of drug clinical trials, and low cost of conducting clinical trials in emerging countries are also driving the growth of the market. The growing numbers of mergers and acquisitions is a key trend observed in the market. Among the various end-user segments of healthcare CRO, the pharmaceutical and biopharmaceutical companies accounted for the largest share in the global market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/contract-research-organization-market/report-sample

CROs provide support and services in form of research facilities outsourced on contract basis to life sciences, pharmaceutical, and medical device industries. The major services offered by CROs include preclinical research, biologic assay development, biopharmaceutical and pharmaceutical development, commercialization, clinical trials management, and clinical research. These organizations also provide support to research organizations, academic institutes, and government organizations.

Apart from these regions, Latin America is another important market. This is due to improving research infrastructure and growing demand of novel pharmaceutical and biopharmaceutical drugs in the region. Brazil holds the largest share in the Latin American market, due to the increasing R&D activities in the country.

Browse Full Report at: https://www.psmarketresearch.com/market-analysis/contract-research-organization-market

Some of the major players operating in the global healthcare CRO market include Laboratory Corporation of America Holdings, Quintiles IMS Holdings, Inc., PAREXEL International Corporation, Charles River Laboratories, Inc., Pharmaceutical Product Development, LLC, ICON plc, PRA Health Sciences, and inVentiv Health, Inc.

 

 

The global medical tourism market is growing significantly due to high cost of healthcare expenditure in developed countries. According to Centers for Disease Control and Prevention, approximately 750,000 U.S. people travel out of the country for medical care each year. In addition, rise in aging population, reduced cost of procedure in developing countries, and high standards of medical care at a reasonable price are expected to support the medical tourism market to grow in the coming years. Aging increases the risk of diseases, such as heart disease, gastrointestinal diseases and lifestyle associated diseases. According to the World Health Organization, the population of 60 years and above is expected to rise to 15% in 2050.

Explore Sample Copy of this Research: https://www.psmarketresearch.com/market-analysis/medical-tourism-market/report-sample

Medical tourism refers to travelling to another country for medical treatment. Patients may go for medical care to another country for a range of reason, such as decreased cost, or to receive a procedure or therapy not available in their country. Services ranging from essential treatment to different kind of alternative treatments are provided through medical tourism. Cosmetic surgery, orthopedic surgery, weight loss surgery, heart surgery, oncologic care, reproductive treatment and dental treatment are some of the common procedures that people undergo on medical tourism.

On the basis of treatment, the medical tourism market can be categorized as dental treatment, orthopedic treatment, cosmetic treatment, cardiovascular treatment, fertility treatment, and general treatment. Cosmetic treatment leads the medical tourism market by treatment type, as cosmetic surgery is costly and is not covered under the health insurance. The oncologic care segment is expected to grow with the highest rate in the coming years, due to rising incidence of cancer cases all over the world.

Explore Report at: https://www.psmarketresearch.com/market-analysis/medical-tourism-market

Some of the hospitals operating in the medical tourism market are Apollo Hospital Enterprise Limited, Asian Heart Institute, Bumrungrad International Hospital, Min-Sheng General Hospital, Min-Sheng General Hospital, KPJ Healthcare Berhad, Bangkok Hospital Medical Center, Fortis Health Ltd., Prince Court Medical Center, Samitivej Sukhumvit, and Raffles Medical Group.